Transporters as Drug Targets: Volume 70

As opposed to other books on the topic, this volume is unique in also covering emerging transporter targets. Following a general introduction to the importance of targeting transporter proteins with drugs, the book systematically presents individual transporter classes and explains their pharmacology and physiology. The text covers all transporter families with known or suspected importance as drug targets, including neurotransmitter transporters, ABC transporters, glucose transporters and organic ion transporters. The final part discusses recent advances in structural studies of transport proteins, assay methods for transport activity, and the systems biology of transporters and their regulation. With its focus on drug development issues, this authoritative overview is required reading for researchers in industry and academia targeting transport proteins for the treatment of disease. INDICE: Preface XIII .A Personal Foreword XVII .1 Insights into Transporter Classifications: an Outline of Transporters as Drug Targets 1Michael Viereck, Anna Gaulton, and Daniela Digles .1.1 Introduction 1 .1.2 Available Transporter Classifications 2 .1.3 Function versus Sequence Similarity 7 .1.4 Merged Top–Level Transporter Classification 7 .1.5 Choice and Design of the New ChEMBL Classification 11 .1.6 Transporter as Drug Targets 12 .1.7 Drug Targets in the SLC Classification 15 .1.8 Conclusions 17 .Acknowledgment 17 .References 18 .2 New Trends in Antidepressant Drug Research 21Benny Bang–Andersen, Klaus P. Bøgesø, Jan Kehler, and Connie Sánchez .2.1 Introduction 21 .2.2 Reuptake Blockers 26 .2.3 Multimodal Drugs 36 .2.4 Conclusions 42 .List of Abbreviations 42 .References 43 .3 The Molecular Basis of the Interaction Between Drugs and Neurotransmitter Transporters 53Harald H. Sitte, Thomas Stockner, and Michael Freissmuth .3.1 Introduction 53 .3.2 Crystal Structures of SLC6 Transporters 55 .3.3 The Binding Site Proper 60 .3.4 The Transport Cycle 61 .3.5 Conclusions and Perspectives 63 .Acknowledgments 64 .References 64 .4 –Aminobutyric Acid and Glycine Neurotransmitter Transporters 69Petrine Wellendorph, Julie Jacobsen, Jonas Skovgaard–Petersen, Andreas Jurik, Stine B. Vogensen, Gerhard Ecker, Arne Schousboe, Povl Krogsgaard–Larsen, and Rasmus P. Clausen .4.1 Introduction 69 .4.2 GABA Transporters 73 .4.3 Glycine Transporters 90 .4.4 Conclusions and Future Perspectives 95 .References 96 .5 ABC Transporters: From Targets to Antitargets and Back 107Gerhard F. Ecker .5.1 Introduction 107 .5.2 ABC Transporter as Drug Targets 109 .5.3 ABC Transporter: from Targets to Antitargets 111 .5.4 Pharmacochaperones and Beyond 113 .5.5 Conclusions and Outlook 114 .Acknowledgment 115 .References 115 .6 ABC Transporters Involved in Cholestasis 119Frans J. C. Cuperus, Julien Gautherot, Emina Halilbasic, Thierry Claudel, and Michael Trauner .6.1 Introduction 119 .6.2 Canalicular ABC Transporters 122 .6.3 Basolateral ABC Transporters 136 .6.4 Nuclear Receptors as Drug Targets 140 .6.5 Ursodeoxycholic Acid Treatment in Cholestatic Liver Disease 144 .6.6 Conclusions 145 .References 145 .7 Recent Advances in Structural Modeling of ABC Transporters 167Dennis Haake, Peter Chiba, and Gerhard F. Ecker .7.1 Introduction 167 .7.2 ABC Transporter Modeling Attempts Since 2001 168 .7.3 Retraction of Five Transporter Structures 170 .7.4 First Mammalian ABC Transporter Structure 173 .7.5 Conclusions and Perspectives 175 .Acknowledgment 175 .References 175 .8 PET Imaging of ABC Transporters at the Blood Brain Barrier 179Oliver Langer .8.1 The Blood Brain Barrier 179 .8.2 The Brain as a Pharmacological Sanctuary 180 .8.3 Implication of ABC Transporters in Neurological Disorders 180 .8.4 Positron Emission Tomography 181 .8.5 PET Imaging of ABC Transporters 181 .8.6 Challenges in Designing PET Tracers for ABC Transporters 184 .8.7 Potential Applications of PET Tracers for ABC Transporters 184 .8.8 Overview of Available PET Tracers for Cerebral ABC Transporters 185 .8.9 Summary 191 .Abbreviations 191 .References 191 .9 The Systems Biology of Transporters Targeting the Regulatory System for Transporters (FXR/RXR) 199Antimo Gioiello, Maura Marinozzi, Bruno Cerra, Chiara Custodi, Roberto Pellicciari, and Antonio Macchiarulo .9.1 Introduction 199 .9.2 Discovery and Pharmacological Characterization of FXR 200 .9.3 Regulation of the Hepatobiliary Transport System by FXR 201 .9.4 Genetic and Structural Properties of FXR 207 .9.5 FXR Ligands 209 .9.6 Conclusions and Perspectives 221 .References 221 .10 ANO1 as a Novel Drug Target 231Anke Bill and Larry Alex Gaither .10.1 Introduction 231 .10.2 ANO1: a Calcium Activated Chloride Channel 232 .10.3 Pharmacological Targeting of ANO1 238 .10.4 ANO1 as a Therapeutic Target 241 .10.5 Concluding Remarks 246 .References 247 .11 Ligand Discovery for the Nutrient Transporters ASCT2 and LAT–1 from Homology Modeling and Virtual Screening 253Claire Colas and Avner Schlessinger .11.1 Solute Carriers in Cancer Metabolism 253 .11.2 In Silico Methods for Structure–based Drug Design 255 .11.3 Emerging Cancer Metabolism Targets 260 .11.4 Conclusions and Future Outlook 263 .Acknowledgment 265 .References 265 .12 Organic Anion Transporting Polypeptides as Drug Targets 271Eleni Kotsampasakou and Gerhard F. Ecker .12.1 Introduction 271 .12.2 OATPs and Genetic Diseases 285 .12.3 OATPs and Cancer 286 .12.4 OATPs as Diagnostic Markers 301 .12.5 OATPs and Selective Delivery of Drugs 301 .12.6 Potential Protective Role of OATPs 309 .12.7 OATPs and Drug Drug Interactions 311 .12.8 Conclusions and Outlook 312 .Acknowledgments 313 .Abbreviation List 313 .References 314 .Index 325

• ISBN: 978-3-527-33384-4
• Editorial: Wiley VCH
• Encuadernacion: Cartoné
• Páginas: 354
• Fecha Publicación: 08/02/2017
• Nº Volúmenes: 1
• Idioma: Inglés